History
The history shows the progress of the company and is not intended to promote or advertise any drugs.
| 2003 | June | Company establishment |
|---|---|---|
| 2004 | April | License agreement with Janssen (LUNABELL®) License agreement with Teva in USA (NOBELZIN®) |
| 2006 | May | Sales alliance with Fuji Pharma (LUNABELL®) |
| 2007 | April | Sales alliance with Alfresa (NOBELZIN®) |
| June | License agreement with Novatech in France (talc) | |
| July | Sales alliance with Nippon Shinyaku (LUNABELL®) | |
| December | License agreement with Pfizer (fosphenytoin) | |
| 2008 | April | Launch of NOBELZIN® for Wilson's disease |
| July | Launch of LUNABELL® (mixed hormone) | |
| December | Launch of NOBELBAR® for neonatal seizures and status epilepticus | |
| 2009 | March | License agreement with Eisai (carmustine wafer for intracranial implantation) |
| November | Opening of Osaka office | |
| 2010 | June | Opening of Tokyo, Nagoya, and Fukuoka offices |
| December | Additional indication of LUNABELL® (functional dysmenorrhea) License agreement with Keocyt in France (streptozocin) |
|
| 2011 | March | Sales alliance with Eisai (Fostoin®) |
| April | Opening of Sapporo office | |
| May | Opening of Sendai office Co-development agreement with Nippon Boehringer (anhydrous caffeine) |
|
| September | License agreement with Clinigen in UK (Foscavir, antiviral chemotherapeutic) | |
| 2012 | January | Approval transfer from AstraZeneca (Foscavir) Launch of Fostoin® for status epilepticus and prevention of postoperative seizure, Co-promotion with Eisai Opening of Tokyo Distribution Center |
| February | Launch of Foscavir through direct sales | |
| June | License agreement with Pfizer (sirolimus) | |
| 2013 | January | Launch of GLIADEL® for malignant glioma Approval transfer from MSD (INDACIN®, COSMEGEN®) |
| June | The 10th Anniversary Opening of Omiya and Yokohama offices |
|
| September | Launch of LUNABELL® tablets ULD for dysmenorrhea Launch of Alabel® oral 1.5 g (aminolevulinic acid) for diagnosis of malignant glioma |
|
| December | Approval transfer to Eisai (GLIADEL®) Launch of Unitalc® for malignant pleural effusion |
|
| 2014 | September | Collaboration with SRI International on endometriosis drug development |
| December | Launch of RAPALIMUS®, world first drug for lymphangioleiomyomatosis (LAM) Launch of Respia® for apnea of prematurity |
|
| 2015 | February | Launch of ZANOSAR® for malignant tumor (gastroenteropancreatic neuroendocrine tumor) Launch of NOBELZIN® tablets Received “the Japan Academic Society of Venture and Entrepreneurs Award” |
| October | Sirolimus received the first “SAKIGAKE” fast-track designation for drugs | |
| 2016 | February | Titanium Bridge received the first “SAKIGAKE” fast-track designation for medical devices |
| November | Marketing approval transferred to Clinigen KK (Foscavir) | |
| 2017 | February | Mr. Shiomura (Managing Director & CEO) won the Minister of Economic, Trade and Industry Prize at Japan Venture Awards 2017 |
| March | Additional indication for NOBELZIN® (hypozincemia) | |
| 2018 | June | Launch of RAPALIMUS® Gel for tuberous sclerosis-associated skin lesions |
| July | Launch of TITANBRIDGE® for adductor spasmodic dysphonia | |
| October | Launch of JEMINA® for dysmenorrhea | |
| 2019 | June | Nobelpharma America, LLC established |
| December | Launch of RETYMPA® for tympanic membrane perforation | |
| 2020 | May | Plusultra pharma GmbH established |
| June | Launch of Melatobel® for sleep-onset difficulty associated with neurodevelopmental disorder in children | |
| September | Direct sales of Fostoin® | |
| December | Jiangsu Nobelpharma Co., Ltd. established | |
| 2021 | Juiy | Communications Depertment established in Administrative Affairs & Corporate Planning Division Compliance Division established |
| September | Additional indication for RAPALIMUS® (refractory lymphatic disease [lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham's disease, lymphangiectasia]) Vaccine Business Division established |
|
| 2022 | January | Domestic Sales & Marketing Division reorganized |
| March | Additional indication for Unitalc® (inoperable secondary intractable pneumothorax) Additional indication for LUNABELL® (coordinating the timing of initiation of modulated ovarian stimulation in assisted reproductive technology) Additional indication for JEMINA® (coordinating the timing of initiation of modulated ovarian stimulation in assisted reproductive technology) HYFTOR® (sirolimus topical gel) approved by FDA Vaccine Business Division renamed to Bio Business Division |
|
| August | HYFTOR® (sirolimus topical gel) launched in the US | |
| 2023 | February | Launch of NOBELZIN® Granules 5% for Wilson's disease and hypozincemia Start of “Inclusive,” information site for daily lives of chiltren with intractable diseases |
| March | “xian luo li” (sirolimus topical gel) approved in China | |
| April | Launch of Zinc Kit “ACCUREAD Zn” (in-vitro diagnostic) and general-purpose spectrophotometric analyzer “ACCUREAD” (medical device) | |
| May | HYFTOR® (sirolimus topical gel) approved in EU | |
| September | HYFTOR® (sirolimus topical gel) approved in United Kingdom |